London Health Sciences Center researchers published a study validating the accuracy of the method as a potential screening test for symptomatic male patients.
Researchers from both teams plan to continue to refine their findings toward creating simple PCR or other nucleic acid amplification-based assays.
ISS astronauts will soon begin testing the Oxford Nanopore MinIon and two PCR platforms while researchers on Earth continue to evaluate microarrays for use in space.
The approach can increase CpG coverage about 18-fold by inferring from existing data to predict methylation of sites outside those covered on the arrays themselves.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
The researchers were able to differentiate among patients with lung cancer, COPD, and health controls using the biomarkers.
The results could inform diagnosis and treatment for PTSD and PTSD-associated and inflammation-associated disorders.
UK-based XRGenomics is using Affymetrix's GeneTitan platform to develop a gene expression signature as a stratification tool for dementia research.
Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.
Athletigen will use the Axiom genotyping platform to process its microarrays analyzing 850,000 genetic variants that could be related to sports performance.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.